Literature DB >> 7599038

Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

H Boukerche1, O Berthier-Vergnes, E Tabone, M Bailly, J F Doré, J L McGregor.   

Abstract

In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 +/- 6 ng TSP 10(-6) cells) and bound to the surface of M3Da. cells via receptors different from CD36, as shown by biosynthetic labelling and immunofluorescence studies. The levels of TSP binding to M3Da. cells evaluated by binding studies, using an anti-TSP monoclonal antibody (MAb) (LYP8), shows 367,000 +/- 58,000 (mean +/- s.d.) LYP8 binding sites per cell with a dissociation constant (Kd) of 67 nM. TSP binding to M3Da. cells shows 400,000 +/- 50,000 TSP binding sites per cell with a Kd of 10 nM. The capacity of anti-TSP MAb (LYP8) to inhibit M3Da.-platelet interactions was followed on an aggregometer and evaluated by electron microscopy studies. The biological role of TSP binding to M3Da. cells was investigated by implanting subcutaneously the M3Da. cell line in nude mice and following the size and time of in vivo tumour growth. Reducing the availability or the functional level of TSP by using an anti-TSP MAb (LYP8) resulted in a significant decrease in platelet aggregates interacting with M3Da. melanoma cells. Using an enzyme-linked immunosorbent assay, purified alpha nu beta 3 was shown to bind TSP. Moreover, LYP8-coated M3Da. cells showed a reduced capacity to form tumours in vivo. M3Da. cells were observed to attach and spread on human platelet TSP-coated plastic wells. This attachment by M3Da. cells was inhibited in a similar way by LYP8 and an anti-alpha nu beta 3 MAb (LYP18). The results obtained in this study show that TSP secreted and bound to the surface of a human melanoma cell line (M3Da.) acts as a link between aggregated platelets and the M3Da. cell surface. Moreover, these results shows that TSP can modulate tumour growth in vivo. Reagents such as MAbs directed against TSP and peptides derived from TSP could not only be used as a new therapeutic approach in the control of tumour metastasis of melanoma, but may also contribute to elucidation of the role of TSP in cancer biology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599038      PMCID: PMC2034115          DOI: 10.1038/bjc.1995.285

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation.

Authors:  J L McGregor; B Catimel; S Parmentier; P Clezardin; M Dechavanne; L L Leung
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

2.  Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity.

Authors:  B L Riser; J Varani; K O'Rourke; V M Dixit
Journal:  Exp Cell Res       Date:  1988-02       Impact factor: 3.905

3.  The GPIIB-IIIa-like complex may function as a human melanoma cell adhesion receptor for thrombospondin.

Authors:  G P Tuszynski; J Karczewski; L Smith; A Murphy; V L Rothman; K A Knudsen
Journal:  Exp Cell Res       Date:  1989-06       Impact factor: 3.905

Review 4.  Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites.

Authors:  G L Nicolson
Journal:  Biochim Biophys Acta       Date:  1988-11-15

5.  Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex.

Authors:  H Boukerche; O Berthier-Vergnes; E Tabone; J F Doré; L L Leung; J L McGregor
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

6.  Interactions of thrombospondin with sulfated glycolipids and proteoglycans of human melanoma cells.

Authors:  D D Roberts
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

7.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

8.  A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; M Bailly; J F Doré; L L Leung; J L McGregor
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

9.  Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells.

Authors:  J Varani; B L Riser; L A Hughes; T E Carey; S E Fligiel; V M Dixit
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

10.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors.

Authors:  J Lawler; R Weinstein; R O Hynes
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  3 in total

Review 1.  Role of platelet adhesion in homeostasis and immunopathology.

Authors:  D N Männel; G E Grau
Journal:  Mol Pathol       Date:  1997-08

2.  Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension.

Authors:  James P Maloney; Robert S Stearman; Todd M Bull; David W Calabrese; Megan L Tripp-Addison; Marilee J Wick; Ulrich Broeckel; Ivan M Robbins; Lisa A Wheeler; Joy D Cogan; James E Loyd
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

3.  Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo.

Authors:  Baogang J Xu; Wenwei Yan; Bojana Jovanovic; Aubie K Shaw; Qi A An; Jimmy Eng; Anna Chytil; Andrew J Link; Harold L Moses
Journal:  Cancer Microenviron       Date:  2010-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.